ADC Therapeutics SA

ADC Therapeutics is a commercial-stage global company focused on antibody drug conjugates (ADCs). The company's primary product is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA has received accelerated approval from the U.S. Food and Drug Administration (FDA) and conditional approval from the European Commission, China National Medical Products Administration (NMPA), and Health Canada. It is approved for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. ADC Therapeutics is expanding ZYNLONTA internationally and into earlier lines of DLBCL through the LOTIS-5 confirmatory Phase 3 clinical trial (rituximab combination) and LOTIS-7 Phase 1b clinical trial (bispecific combination). The company is also exploring ZYNLONTA's use in indolent lymphomas, including marginal zone lymphoma (MZL) and follicular lymphoma (FL), through investigator-initiated trials (IITs). Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics manages specialized capabilities spanning clinical development, manufacturing, and commercialization. The company completed IND-enabling activities for ADCT-241, an exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC, at the end of 2025. ADC Therapeutics utilizes its in-house chemistry, manufacturing and controls (CMC) capabilities and an external manufacturing network of third-party contract manufacturing organizations (CMOs) for highly potent molecules and complex biologics.